| Nov 12 |
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
|
| Nov 7 |
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
|
| Sep 11 |
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 13 |
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 13 |
Xenetic Biosciences: Q2 Earnings Snapshot
|
